HOTH - Hoth therapeutics signs production agreement for HT-001 Shares up 75%

Biopharmaceutical company Hoth Therapeutics (HOTH) has signed a production agreement for both GLP and GMP materials associated with HT-001 with Tergus Pharma for its novel cancer treatment. The update follows the recent news that Hoth has requested a Pre-Investigational New Drug ((IND)) meeting to the FDA to discuss a proposed drug development program for the treatment. HT-001 is a topical formulation designed for the treatment of patients with mild to moderate rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor ((EGFR)) inhibitor therapy.Shares have lost more than 70% of their value this year, is up 75% premarket.

For further details see:

Hoth therapeutics signs production agreement for HT-001, Shares up 75%